Vecabrutinib | SNS-062 | BTK/ITK Inhibitor | AmBeed-信号通路专用抑制剂

首页 / 抑制剂/激动剂 / / / Vecabrutinib

Vecabrutinib {[allProObj[0].p_purity_real_show]}

货号：A586120 同义名： SNS-062

Vecabrutinib是一种强效的 BTK 抑制剂，对 WT BTK 和 C481S BTK 的 IC50 分别为 4.6 nM 和 1.1 nM，同时还抑制 ITK 活性（IC50 = 24 nM）。

Vecabrutinib 化学结构
CAS号：1510829-06-7

Vecabrutinib 3D分子结构
CAS号：1510829-06-7

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Vecabrutinib 纯度/质量文件产品仅供科研

货号：A586120 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Neuron, 2025. Ambeed. [ A1440350 ]; • Nature Communications, 2025, 16, 996. Ambeed. [ A111960 , A505336 ]; • JACS, 2025. Ambeed. [ A349578 , A2270125 ]; • PLoS Biol., 2025, 23(2): e3002961. Ambeed. [ A181909 ]; • Redox Rep., 2025, 30(1): 2454887. Ambeed. [ A1155014 ]; 更多 >

BTK 亚型比较

产品名称	BTK ↓ ↑	纯度
CGI-1746	+++ BTK, IC50: 1.9 nM	99% (HPLC)
Spebrutinib	++++ BTK, IC50: <0.5 nM	98+%
Acalabrutinib	++ BTK, IC50: 3nM	98%
CNX-774	+++ BTK, IC50: <1 nM	99%+
Ibrutinib	++++ BTK, IC50: 0.5 nM	98%
ONO-4059 analog	+ BTK, IC50: 23.9 nM	98%
RN486	++ BTK, IC50: 4 nM	99%+
(Z)-LFM-A13	+ BTK, Ki: 1.4 μM	99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Vecabrutinib 生物活性

描述

Bruton’s tyrosine kinase (BTK), a member of the Tec family of tyrosine kinases and expressed in B cells, macrophages, and monocytes but not in T cells, plays a crucial role in signaling through the B cell receptor (BCR) and the Fcγ receptor (FcγR) in B cells and myeloid cells, respectively ^[1]. Vecabrutinib is a potent, noncovalent BTK and ITK (interleukin-2-inducible kinase) inhibitor, with K_d of 0.3 nM and 2.2 nM, respectively. It inhibits WT and C481S BTK with IC₅₀s of 2.9 nM and 4.4 nM, respectively. Vecabrutinib decreases viability of primary CLL cells in the presence of HS5 stromal protection by 5.5%. Vecabrutinib has good oral bioavailability in rat and dog (%F ≥ 40%) and a terminal half-life of 5 to 6 hours and is well tolerated with continuous drug levels.

Vecabrutinib 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT03037645	Chronic Lymphocytic Leukemia ... 展开 >> Small Lymphocytic Lymphoma Lymphoplasmacytoid Lymphoma Mantle-Cell Lymphoma Waldenstrom Macroglobulinemia Diffuse Large B Cell Lymphoma Follicular Lymphoma 收起 <<	Phase 1 Phase 2	Recruiting	June 30, 2021	United States, California ... 展开 >> University of California Irvine Medical Center Recruiting Orange, California, United States, 92868-3201 Contact: General Contact 877-827-8839 ucstudy@uci.edu UC San Diego Moores Cancer Center Recruiting San Diego, California, United States, 92093 Contact: Barbara Ivers 858-822-6281 bivers@ucsd.edu United States, Florida Moffitt Cancer Center and Research Institute Recruiting Tampa, Florida, United States, 33612 Contact: Natalie Miller 813-745-2591 Natalie.Miller@moffitt.org United States, Massachusetts Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Conner Shaughnessy 617-582-8437 Conner_Shaughnessy@dfci.harvard.edu United States, New York Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Isaac Deonarine 646-888-1319 deonarii@mskcc.org Weill Cornell Medicine Recruiting New York, New York, United States, 10065 Contact: Jessica Harper 646-962-9414 jah2070@med.cornell.edu United States, Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Chongjuan Wei 713-792-3530 cwei@mdanderson.org United States, Washington Swedish Cancer Institute Recruiting Seattle, Washington, United States, 98104 Contact: Ngan Trinh 206-215-2363 Ngan.Trinh@Swedish.org 收起 <<

Vecabrutinib 参考文献

[1]Caldwell RD, Qiu H, Askew BC, Bender AT, Brugger N, Camps M, Dhanabal M, Dutt V, Eichhorn T, Gardberg AS, Goutopoulos A, Grenningloh R, Head J, Healey B, Hodous BL, Huck BR, Johnson TL, Jones C, Jones RC, Mochalkin I, Morandi F, Nguyen N, Meyring M, Potnick JR, Santos DC, Schmidt R, Sherer B, Shutes A, Urbahns K, Follis AV, Wegener AA, Zimmerli SC, Liu-Bujalski L. Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases. J Med Chem. 2019 Sep 12;62(17):7643-7655. doi: 10.1021/acs.jmedchem.9b00794. Epub 2019 Aug 15. PMID: 31368705.

Vecabrutinib 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

1.89mL

0.38mL

0.19mL

9.44mL

1.89mL

0.94mL

18.87mL

3.77mL

1.89mL

Vecabrutinib 技术信息

CAS号	1510829-06-7
分子式	C₂₂H₂₄ClF₄N₇O₂
分子量	529.918

别名	SNS-062
运输	蓝冰

存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Keep in dark place,Sealed in dry,Store in freezer, under -20°C

溶解方案

细胞实验：

DMSO: 120 mg/mL(226.45 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

方案二

动物实验配方

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT03037645

Chronic Lymphocytic Leukemia ... 展开 >> Small Lymphocytic Lymphoma Lymphoplasmacytoid Lymphoma Mantle-Cell Lymphoma Waldenstrom Macroglobulinemia Diffuse Large B Cell Lymphoma Follicular Lymphoma 收起 <<

Phase 1 Phase 2

Recruiting

June 30, 2021

United States, California ... 展开 >> University of California Irvine Medical Center Recruiting Orange, California, United States, 92868-3201 Contact: General Contact 877-827-8839 ucstudy@uci.edu UC San Diego Moores Cancer Center Recruiting San Diego, California, United States, 92093 Contact: Barbara Ivers 858-822-6281 bivers@ucsd.edu United States, Florida Moffitt Cancer Center and Research Institute Recruiting Tampa, Florida, United States, 33612 Contact: Natalie Miller 813-745-2591 Natalie.Miller@moffitt.org United States, Massachusetts Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Conner Shaughnessy 617-582-8437 Conner_Shaughnessy@dfci.harvard.edu United States, New York Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Isaac Deonarine 646-888-1319 deonarii@mskcc.org Weill Cornell Medicine Recruiting New York, New York, United States, 10065 Contact: Jessica Harper 646-962-9414 jah2070@med.cornell.edu United States, Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Chongjuan Wei 713-792-3530 cwei@mdanderson.org United States, Washington Swedish Cancer Institute Recruiting Seattle, Washington, United States, 98104 Contact: Ngan Trinh 206-215-2363 Ngan.Trinh@Swedish.org 收起 <<

Vecabrutinib {[allProObj[0].p_purity_real_show]}

Vecabrutinib 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Vecabrutinib 质控信息

Vecabrutinib 生物活性

Vecabrutinib 临床研究

Vecabrutinib 参考文献

Vecabrutinib 实验方案

Vecabrutinib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Vecabrutinib {[allProObj[0].p_purity_real_show]}

Vecabrutinib 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Vecabrutinib 质控信息

Vecabrutinib 生物活性

Vecabrutinib 临床研究

Vecabrutinib 参考文献

Vecabrutinib 实验方案

Vecabrutinib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Vecabrutinib 纯度/质量文件产品仅供科研